130 related articles for article (PubMed ID: 38116031)
1. Patterns of Glucose Metabolism in [
Lee JJ; Earnest T; Ha SM; Bani A; Kothapalli D; Liu P; Sotiras A
medRxiv; 2023 Nov; ():. PubMed ID: 38116031
[TBL] [Abstract][Full Text] [Related]
2. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
3. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
4. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
[TBL] [Abstract][Full Text] [Related]
9. Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease.
Iaccarino L; Llibre-Guerra JJ; McDade E; Edwards L; Gordon B; Benzinger T; Hassenstab J; Kramer JH; Li Y; Miller BL; Miller Z; Morris JC; Mundada N; Perrin RJ; Rosen HJ; Soleimani-Meigooni D; Strom A; Tsoy E; Wang G; Xiong C; Allegri R; Chrem P; Vazquez S; Berman SB; Chhatwal J; Masters CL; Farlow MR; Jucker M; Levin J; Salloway S; Fox NC; Day GS; Gorno-Tempini ML; Boxer AL; La Joie R; Bateman R; Rabinovici GD
Brain Commun; 2024; 6(3):fcae159. PubMed ID: 38784820
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
11. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
12. Association between white matter lesions and the cerebral glucose metabolism in patients with cognitive impairment.
No HJ; Yi HA; Won KS; Chang HW; Kim HW
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(3):160-166. PubMed ID: 31053556
[TBL] [Abstract][Full Text] [Related]
13. Regional brain hypometabolism is unrelated to regional amyloid plaque burden.
Altmann A; Ng B; Landau SM; Jagust WJ; Greicius MD;
Brain; 2015 Dec; 138(Pt 12):3734-46. PubMed ID: 26419799
[TBL] [Abstract][Full Text] [Related]
14. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
[TBL] [Abstract][Full Text] [Related]
15. Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration - A combined MRI & FDG-PET study.
Woost TB; Dukart J; Frisch S; Barthel H; Sabri O; Mueller K; Schroeter ML
Neuroimage Clin; 2013; 2():746-58. PubMed ID: 24179826
[TBL] [Abstract][Full Text] [Related]
16. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging.
Vannini P; Hanseeuw B; Munro CE; Amariglio RE; Marshall GA; Rentz DM; Pascual-Leone A; Johnson KA; Sperling RA
Neuroimage Clin; 2017; 15():408-414. PubMed ID: 28616381
[TBL] [Abstract][Full Text] [Related]
17. Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.
Knopman DS; Jack CR; Lundt ES; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Machulda MM; Roberts RO; Boeve BF; Jones DT; Petersen RC
JAMA Neurol; 2015 Dec; 72(12):1475-83. PubMed ID: 26437123
[TBL] [Abstract][Full Text] [Related]
18. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
19. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.
Paranjpe MD; Chen X; Liu M; Paranjpe I; Leal JP; Wang R; Pomper MG; Wong DF; Benzinger TLS; Zhou Y;
Neuroimage Clin; 2019; 22():101795. PubMed ID: 30991617
[TBL] [Abstract][Full Text] [Related]
20. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]